Stocks-ITCI-Intra-Cellular Therapies Inc

ITCI Intra-Cellular Therapies Inc

70.09 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Intra-Cellular Therapies Inc's revenues increased by 198.69% and amounted to 250.31M. Net income increased by 9.81% to -256.26M. Net assets increased by 57.00% to 656.07M and EPS increased from -3.50 to -2.72.
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
Net Profit Margin
Operating Margin
Return On Investment